These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 30797988)

  • 1. Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system.
    Momtazi-Borojeni AA; Jaafari MR; Badiee A; Sahebkar A
    Atherosclerosis; 2019 Apr; 283():69-78. PubMed ID: 30797988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis.
    Momtazi-Borojeni AA; Jaafari MR; Badiee A; Banach M; Sahebkar A
    BMC Med; 2019 Dec; 17(1):223. PubMed ID: 31818299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis.
    Momtazi-Borojeni AA; Jaafari MR; Afshar M; Banach M; Sahebkar A
    Arch Med Sci; 2021; 17(5):1365-1377. PubMed ID: 34522266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates.
    Momtazi-Borojeni AA; Jaafari MR; Banach M; Gorabi AM; Sahraei H; Sahebkar A
    Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of PCSK9 Immunization on Glycemic Indices in Diabetic Rats.
    Momtazi-Borojeni AA; Jaafari MR; Abdollahi E; Banach M; Sahebkar A
    J Diabetes Res; 2021; 2021():4757170. PubMed ID: 34504898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management.
    Galabova G; Brunner S; Winsauer G; Juno C; Wanko B; Mairhofer A; Lührs P; Schneeberger A; von Bonin A; Mattner F; Schmidt W; Staffler G
    PLoS One; 2014; 9(12):e114469. PubMed ID: 25474576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of immunization against PCSK9 in an experimental model of breast cancer.
    Momtazi-Borojeni AA; Nik ME; Jaafari MR; Banach M; Sahebkar A
    Arch Med Sci; 2019 May; 15(3):570-579. PubMed ID: 31110521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer.
    Momtazi-Borojeni AA; Nik ME; Jaafari MR; Banach M; Sahebkar A
    Arch Med Sci; 2019 May; 15(3):559-569. PubMed ID: 31110520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice.
    Kawakami R; Nozato Y; Nakagami H; Ikeda Y; Shimamura M; Yoshida S; Sun J; Kawano T; Takami Y; Noma T; Rakugi H; Minamino T; Morishita R
    PLoS One; 2018; 13(2):e0191895. PubMed ID: 29438441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Immunogenic Potential of PCSK9 Peptide Vaccine in Mice.
    Ataei S; Momtazi-Borojeni AA; Ganjali S; Banach M; Sahebkar A
    Curr Med Chem; 2023; 30(26):3024-3031. PubMed ID: 36200256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical toxicity assessment of a peptide-based antiPCSK9 vaccine in healthy mice.
    Momtazi-Borojeni AA; Banach M; Tabatabaei SA; Sahebkar A
    Biomed Pharmacother; 2023 Feb; 158():114170. PubMed ID: 36587555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of immunisation against PCSK9 in mice bearing melanoma.
    Momtazi-Borojeni AA; Nik ME; Jaafari MR; Banach M; Sahebkar A
    Arch Med Sci; 2020; 16(1):189-199. PubMed ID: 32051723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin/kexin type 9.
    Chackerian B; Remaley A
    Curr Opin Lipidol; 2016 Aug; 27(4):345-50. PubMed ID: 27389630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Therapeutic Peptide Vaccine Against PCSK9.
    Pan Y; Zhou Y; Wu H; Chen X; Hu X; Zhang H; Zhou Z; Qiu Z; Liao Y
    Sci Rep; 2017 Oct; 7(1):12534. PubMed ID: 28970592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia?
    Weisshaar S; Zeitlinger M
    Drugs; 2018 Jun; 78(8):799-808. PubMed ID: 29737499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.
    Landlinger C; Pouwer MG; Juno C; van der Hoorn JWA; Pieterman EJ; Jukema JW; Staffler G; Princen HMG; Galabova G
    Eur Heart J; 2017 Aug; 38(32):2499-2507. PubMed ID: 28637178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.
    Seidah NG; Prat A; Pirillo A; Catapano AL; Norata GD
    Cardiovasc Res; 2019 Mar; 115(3):510-518. PubMed ID: 30629143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials.
    Bai J; Gong LL; Li QF; Wang ZH
    J Clin Lipidol; 2018; 12(2):277-291.e3. PubMed ID: 29428832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesterol reduction by immunization with a PCSK9 mimic.
    Zhang B; Chuang GY; Biju A; Biner D; Cheng J; Wang Y; Bao S; Chao CW; Lei H; Liu T; Nazzari AF; Yang Y; Zhou T; Chen SJ; Chen X; Kong WP; Ou L; Parchment DK; Sarfo EK; SiMa H; Todd JP; Wang S; Woodward RA; Cheng C; Rawi R; Mascola JR; Kwong PD
    Cell Rep; 2024 Jun; 43(6):114285. PubMed ID: 38819987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
    Schiele F; Park J; Redemann N; Luippold G; Nar H
    J Mol Biol; 2014 Feb; 426(4):843-52. PubMed ID: 24252255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.